Playback speed
10 seconds
0 views
September 1, 2020
This animation provides an overview of CCM therapy including the indications for use, recommendations for patient selection, and a brief review of mechanism of action.
- October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Comments 0
Login to view comments.
Click here to Login